Gareth Macdonald

2 weeks ago | genengnews.com | Gareth Macdonald

Home Topics Bioprocessing Digitization is a Priority for Sustainable Pharma Source: 4-X Image/Getty Images "Digital architecture" will help drug makers use data to drive digitization of manufacturing operations says UK Centre for Process Innovation [4-X Image/Getty Images] Digitization “future proofs” drug manufacturing according to the U.K. Centre for Process Innovation (CPI), which says a new blueprint will help biopharmaceutical firms navigate a digital overhaul.

2 weeks ago | informaconnect.com | Gareth Macdonald

Data generated in clinical trials has improved over the past decade due, in part, to efforts to include participants from minority and traditionally underrepresented groups. The conclusion comes from an Association of Clinical Research Professionals (ACRP) survey which quizzed CROs, research sites and academics about the trials sector and found, in general, that things are improving.

2 weeks ago | informaconnect.com | Gareth Macdonald

Clinical intelligence firm Lokavant has released an AI-based clinical trial forecasting technology it claims will help sponsors identify the best site and country combinations for their drug study programmes. The system – called Spectrum v15 – uses a combination of AI models trained on a data set of 500,000 trials to predict the probability of achieving key last-patient-in targets.

3 weeks ago | genengnews.com | Gareth Macdonald

Home Topics Bioprocessing AI and Automation Skills Critical for Future Biopharma Engineers AI and automation skills will be in demand as biopharma embraces digitization according to Atlantic Technological University expert [Tahreer Photography/Getty Images] The next generation of biopharmaceutical engineers will need hands-on experience with AI and process automation in regulated environments, as well as the adaptability to learn new skills, for a successful career.

3 weeks ago | informaconnect.com | Gareth Macdonald

Psyence BioMed has hired Southern Star Research to run a clinical trial of the magic mushroom-derivative psilocybin in patients with adjustment disorder. The study — a Phase IIb trial — will examine the drug as a treatment for the psychological condition in people diagnosed with cancer. According to a recently published letter of intent, Sydney, Australia-based contractor Southern Star will manage the study at sites across the country.